curriculumvitae.doc
Upcoming SlideShare
Loading in...5
×
 

Like this? Share it with your network

Share

curriculumvitae.doc

on

  • 743 views

 

Statistics

Views

Total Views
743
Views on SlideShare
743
Embed Views
0

Actions

Likes
0
Downloads
2
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft Word

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

curriculumvitae.doc Document Transcript

  • 1. A. Maziar Zafari Curriculum Vitae CURRICULUM VITAE Revised: 05/21/2003 1. Name: A. Maziar Zafari, M.D., Ph.D. 2. Current Titles and Affiliations: a. Academic appointments: Assistant Professor of Medicine (Cardiology) Emory University School of Medicine b. Clinical appointments: Director, CCU, Atlanta VAMC 3. Birth Date and Place: 03/03/1962 Heidelberg, Germany 4. Citizenship: Stateless, permanent resident 5. Home Address: 2749 Harrington Drive Decatur, GA 30033 Phone: (404) 633 8586 6. Office Address: Atlanta VAMC Division of Cardiology, Rm 2A189 1670 Clairmont Road Decatur, GA 30033 Phone: (404) 321 6111, ext. 7359 FAX: (404) 329 2211 7. E-mail Address: azafari@emory.edu 8. Licensure/Boards: 1989 ECFMG, 423-234-4 1989 FLEX, 620303003 1994 Georgia Medical Board, 39018 9. Education: 1988 M.D., University of Cologne, Volker Diehl, M.D. 1990 Ph.D., University of Cologne, Karl Köhle, M.D. 10. Postgraduate Training: 1990-1993 Primary Care/Internal Medicine Stephen J. Huot, M.D., Ph.D. 1
  • 2. A. Maziar Zafari Curriculum Vitae 1994-1996 Vascular Biology Fellowship Kathy K. Griendling, Ph.D. 1994-1998 Cardiovascular Fellowship R. Wayne Alexander, M.D., Ph.D. 11. Specialty Boards: 1996 ABIM/Internal Medicine 1998 ABIM/Cardiovascular Disease 12. Military or Government Service: 1998-present Staff Cardiologist, Atlanta VAMC 13. Previous Academic and Professional Appointments: 1993-1994 Clinical Instructor, Yale University School of Medicine 14. Previous Administrative Appointments: 1993-1994 Chief Medical Resident, Yale Primary Care Program 15. Committee Memberships: 1992-1993 Member, Yale University School of Medicine, Department of Medicine, Internship Selection Committee 1993-1994 Member, Yale University School of Medicine, Department of Medicine, Internship Selection Committee 1993-1994 Member, Yale University School of Medicine, Department of Medicine, Residency Review Committee 2000-present Chairman, CPR Committee, Atlanta VAMC 2002-present Chairman, Critical Care Committee, Atlanta VAMC 17. Editorships: 2002 Guest Editor, May/June issue of Congestive Heart Failure, a bi-monthly publication 2002-present Series Editor, Hospital Physician Cardiology Board Review Manual, a bi- monthly publication 18. Manuscript reviewer: 1999-present Archives of Physical Medicine and Rehabilitation 2001-present Metabolism 2002-present Hospital Physician 2
  • 3. A. Maziar Zafari Curriculum Vitae 2002-present Journal of the American College of Cardiology 2002-present Heart 2002-present Free Radical Biology & Medicine 2003-present European Journal of Heart Failure 19. Honors and Awards: 1987-1988 Award for Academic Achievement, University of Cologne School of Medicine, DM6,000 1992 First Prize Winner, Resident Presentations, ACP 1992 Resident of the Year, Yale University School of Medicine 1999 Emory University Research Committee Award, $30,000 2000 Emory University, Division of Cardiology, Excellence in Teaching Award 2002 Emory University, Division of Cardiology, Excellence in Teaching Award 2002 Emory University, Department of Medicine, Internal Medicine Residency Program, Attending Teaching Award 20. Society Memberships: 1997 Member, American College of Physicians 1999 Member, American Heart Association 2000 Fellow, American College of Cardiology 2000 Member, American Association for the Advancement of Science 22. Research focus: Investigations in vascular biology to further understand the contribution of oxidative stress and chronic infections to the process of atherosclerosis. Further characterization of the vascular and phagocytic NAD(P)H oxidases in order to investigate a possible role of genetic polymorphisms in atherogenesis, and with severity and extent of coronary atherosclerosis in subjects with and without coronary artery disease. 24. Grant Support: a. Active support: 1. Federally funded: 2003, PI, Department of Veterans Affairs, Medical Research Service, Shared Equipment Evaluation Program (ShEEP) Grant, $44,120. 2. Private foundation funded: 1999-2001, P.I., Emory University Research Committee, p22phox Polymorphisms of 3
  • 4. A. Maziar Zafari Curriculum Vitae the NAD(P)H Oxidase in Patients With and Without Coronary Heart Disease: A Novel Coronary Risk Factor? Research Award, $30,000. 2001-2003, P.I., American Heart Association-Southeast Affiliate, The Effect of p22phox Genotypes on Phagocytic Respiratory Burst Activity in Young Adults without Coronary Artery Disease, Beginning Grant-In-Aid, $100,000. 3. Industry funded: 2000-2001, P.I. for the VAMC Atlanta site: A Multicenter, Randomized, Double- Blind, Placebo-Controlled Study of the Hemodynamic and Clinical Effects of Natrecor (nesiritide) Compared with Nitroglycerin Therapy for Symptomatic Decompensated CHF, SCIOS, $15,000. 2001-2002, P.I. for the VAMC Atlanta site: Prospective Randomized Outcomes Study of Acutely Decompensated CHF Treated Initially in Outpatients With Natrecor: The PROACTION Trial, SCIOS, $5,000. 2001-2003, Co-Investigator for the VAMC Atlanta site: A Clinical Evaluation Comparing Tc-99m TEBOROXIME and Tc-99m SESTAMIBI With Pharmacologic Stress as Well as Coronary Angiography in Patients With and Without Coronary Artery Disease, CardioTec, $39,000. 2002, educational grant for the Emory/VAMC Division of Cardiology to teach coronary anatomy and techniques of left and right heart catheterization and coronary angiography on custom-made anatomical models to cardiology fellows, medical residents and students. Pfizer Inc., $1,000. 25. Clinical Service Contributions: 1. Left and right heart catheterization. 2. Transthoracic, stress and transesophageal echocardiography. 3. Exercise-, Holter- and signal-averaged electrocardiography; tilt table testing. 4. Supervision of the General Cardiology and Congestive Heart Failure Clinics. 5. CCU and cardiology consultation services. 26. Formal Teaching: a. Medical Student Teaching 1993-1994 Sophomore Clinical Methods, Yale University School of Medicine 1998-2001 Sophomore Clinical Methods, Emory University School of Medicine 4
  • 5. A. Maziar Zafari Curriculum Vitae 2001-2003 Sophomore Elective in Cardiology, Emory University School of Medicine 2001-2003 M3 Teaching Course, Emory University School of Medicine 1999-2002 Junior Oral Examinations, Emory University School of Medicine b. Graduate Program 2. Residency program 1998-2003 Vascular Biology Series, cardiology fellows 2000-2003 Core Curriculum Lecture, medical residents 27. Supervisory Teaching: c. Residency Program 1998-2003 medical residents on cardiology consultative service and CCU rotations 2000-2003 medical residents on cardiology research elective rotations (A. Sheikh, M.D.; E. Chun, M.D.; B. Ali, M.D.; A. Vidal, M.D.) 1998-2003 cardiology fellows in clinical, invasive and noninvasive cardiology 2000-2002 clinical research of senior cardiology fellow (Keith E. Wyche, M.D.) 28. Lectureships, Seminar Invitations, and Visiting Professorships: 1999 Columbus Regional Hospital, Department of Medicine: Oxidative Stress and Cardiovascular Disease. 1999 Emory University School of Medicine, Division of Cardiology: The Vascular NADH/NADPH Oxidase. 1999 Emory University School of Medicine, Division of Cardiology: Regulation of Blood Pressure and Homeostatic Mechanisms. 1999 Emory University School of Medicine, Division of Cardiology: The Glycoprotein IIb/IIIa Inhibitors. 1999 Emory University School of Medicine, Division of Cardiology: Endorgan Damage in Hypertension. 1999 Emory University School of Medicine, Division of Cardiology: Renal Function and Hypertension. 1999 Emory University School of Medicine, Division of Cardiology: The Hyperlipidemic States. 1999 Emory University School of Medicine, Division of Cardiology: The Economics of Hypertension. 1999 Grady Memorial Hospital, Division of Cardiology: Oxidative Stress and Cardiovascular Disease. 1999 Emory University School of Medicine, Division of Cardiology: DNA Polymorphisms and Risk for CHD. 1999 Sumter Regional Hospital, Department of Medicine: Malignant Hypertension. 5
  • 6. A. Maziar Zafari Curriculum Vitae 1999 Emory University School of Medicine, VAMC Atlanta: Diagnosis and Management of Acute Myocardial Infarction. 1999 Saint Vincent’s Medical Center, Department of Medicine: Oxidative Stress and Cardiovascular Disease. 2000 University of Utah School of Medicine, Division of Nephrology: Oxidative Stress and Cardiovascular Disease. 2000 Emory University School of Medicine, Department of Medicine, Grady Memorial Hospital: Diagnosis and Management of Hypertensive Emergencies. 2000 Emory University School of Medicine, Division of Cardiology: Genetic Polymorphisms in CHD - The p22phox Polymorphisms. 2000 Emory University School of Medicine, Department of Medicine: Acute Myocardial Infarction - Diagnosis and Management. 2001 Emory University School of Medicine, Department of Medicine, Grady Memorial Hospital: Management of Hypertensive Crisis. 2001 Emory University School of Medicine: p22phox Polymorphisms and CHD - The Need for Physiological Genomics. 2001 Emory University School of Medicine, Department of Medicine, VAMC Atlanta: Early Defibrillation - The Role of the Automated External Defibrillator. 2002 Emory University School of Medicine, Division of Cardiology: Exercise Testing and Stress Echocardiography in Patients With Coronary Artery Disease. 2002 Emory University School of Medicine, Division of Cardiology: Chimerism in the Heart. 2002 Emory University School of Medicine, Department of Medicine, VAMC Atlanta, Early Defibrillation - The Role of the Automated External Defibrillator. 2002 Emory University School of Medicine, Division of Cardiology: Hypertension - A Historical Overview. 2002 Emory University School of Medicine, Division of Cardiology: Endorgan Damage in Hypertension. 2002 DeKalb Medical Center, Department of Medicine: Use of Human B-Type Natriuretic Peptide in the Management of Acutely Decompensated Congestive Heart Failure Patients. 2002 Yale University School of Medicine, Waterbury Hospital Health Center, Department of Medicine: Vascular Oxidative Stress - Physiological and Pathophysiological Roles of the NAD(P)H Oxidases. 2002 Yale University School of Medicine, Saint Mary’s Hospital, Department of Medicine: Vascular Oxidative Stress - Physiological and Pathophysiological Roles of the NAD(P)H Oxidases. 2002 Emory University School of Medicine, Division of Cardiology: Adrenergic Polymorphisms and Heart Failure. 2003 Emory University School of Medicine, Department of Medicine, Grady Memorial Hospital: Diagnosis and Management of Hypertensive Crisis. 2003 Emory University School of Medicine, Department of Medicine, VAMC Atlanta: In-Hospital Resuscitation - The Role of Early Defibrillation. 6
  • 7. A. Maziar Zafari Curriculum Vitae 29. Invitations to National or International Conferences: 1996 ASBMB/ASIP/AAI Joint Meeting, New Orleans, LA: Arachidonic Acid Metabolites Mediate Angiotensin II-induced Hypertrophy by Stimulation of NADH/NADPH Oxidase Activity in Cultured Vascular Smooth Muscle Cells. 1996 Society for Physical Regulation in Biology and Medicine, Chicago, IL: Cyclic Strain Induces an Oxidative Stress and Increases PLA2 Activity in Endothelial Cells. 1996 American Heart Association Scientific Sessions, New Orleans, LA: Angiotensin II Increases Intracellular NADH/NADPH Oxidase-dependent Hydrogen Peroxide in Cultured Vascular Smooth Muscle Cells. 2000 American Heart Association Scientific Sessions, New Orleans, LA: The A640G p22phox Polymorphism in Coronary Artery Disease. 2001 American Heart Association, Scientific Conference on Molecular, Integrative, and Clinical Approaches to Myocardial Ischemia, Seattle, WA: The C242T p22phox Polymorphism of the NADPH Oxidase is Associated With Reduced Superoxide Production in Human Neutrophils. 2001 American Heart Association Scientific Sessions, Anaheim, CA: The C242T p22phox Polymorphism of the NADPH Oxidase is Associated With Reduced Superoxide Production in Human Neutrophils. 2002 American Heart Association Scientific Sessions, Chicago, IL: Improved Resuscitation Efficacy with a Program Emphasizing In-Hospital Early Defibrillation. 2002 Oxygen Society, San Antonio, TX: The eNOS4 Polymorphism Does Not Predict Severity of CAD. 2003 American Society of Nuclear Cardiology, Indianapolis, IN: Teboroxime vs Sestamibi: Comparison of Three Quantitative Indices. 31. Bibliography: a. Published and accepted research articles (clinical, basic science, other) in refereed journals: 1. Zafari AM, Davidoff MN, Austin H, Valppu L, Cotsonis G, Lassègue B, Griendling KK. The A640G and C242T p22phox Polymorphisms in Patients with Coronary Artery Disease. Antiox Redox Signal 2002;4:675-680. 2. Tuli A, Lim SS, Zafari AM. An Unusual Case of Groin Discomfort. Cathet Cardiovasc Diagn 2001;52:484-485. 3. Zafari AM, Ushio-Fukai M, Minieri CA, Akers M, Lassègue B, Griendling KK. Arachidonic Acid Metabolites Mediate Angiotensin II-induced NADH/NADPH Oxidase Activity and Hypertrophy in Vascular Smooth Muscle Cells. Antiox Redox Signal 1999;1:167-179. 3. Zafari AM, Ushio-Fukai M, Akers M, Qiqin Y, Shah A, Harrison DG, Taylor WR, Griendling KK. Role of NADH/NADPH Oxidase-derived H2O2 in Angiotensin II- 7
  • 8. A. Maziar Zafari Curriculum Vitae Induced Vascular Hypertrophy. Hypertension 1998;32:488-495. 4. Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, Griendling KK. p22 phox is a Critical Component of the Superoxide-generating NADH/NADPH Oxidase System and Regulates Angiotensin II-induced Hypertrophy in Vascular Smooth Muscle Cells. J Biol Chem 1996;271:23317-23321. 5. Shirani J, Zafari AM, Roberts WC. Morphologic Features of Fossa Ovalis Membrane Aneurysm in the Adult and Its Clinical Significance. J Am Coll Card 1995;26:466-471. 6. Shirani J, Zafari AM, Roberts WC. Long Asymptomatic Survival with a Bullet Adjacent to the Left Main Coronary Artery, the Only Site of Atherosclerotic Plaque in the Coronary Tree. Am Heart J 1994;128:1043-1044. 7. Shirani J, Zafari AM, Roberts WC. Sudden Death, Right Ventricular Infarction, and Abnormal Right Ventricular Intramural Coronary Arteries in Isolated Congenital Valvular Pulmonic Stenosis. Am J Cardiol 1993;72:368-370. b. Manuscripts submitted: 1. Zafari AM, Zarter SK, Heggen V, Wilson P, Taylor RA, Sternberg M, Dudley SC Jr. Improved In-Hospital Resuscitation Efficacy with a Program Emphasizing Biphasic Waveform Devices and Selective AED Use. J Am Coll Card. 2. Rao S, Austin H, Davidoff MN, Zafari AM. Endothelial Nitric Oxide Synthase Intron 4 Polymorphism and Coronary Artery Disease. FRBM. c. Review articles: 1. Wyche K, Nicholson WJ, Zafari AM. Case Studies in Primary Hypertension. Hosp Phys Cardiology Board Review Manual 2003, 9 (Part 1):1-12. 2. Alameddine FMF, Zafari AM. Genetic Polymorphisms and Oxidative Stress in Heart Failure. Congest Heart Fail 2002;8:157-164. 3. Wyche K, Zafari AM. Diagnosis and Treatment of Primary Hypertension. Hosp Phys Cardiology Board Review Manual 2002, 8 (Part 1):1-12. 4. Zafari AM. Genetic Polymorphisms in Coronary Heart Disease. Hosp Phys Cardiology Board Review Manual 2000, 6 (Part 4):1-12. 5. Zafari AM. Anticoagulant Therapy for Coronary Heart Disease: Case Studies. Hosp Phys Cardiology Board Review Manual 2000, 6 (Part 1):1-12. 6. Zafari AM. Antiplatelet Agents in Coronary Heart Disease: Case Studies. Hosp Phys Cardiology Board Review Manual 1999, 5 (Part 6):1-12. 7. Zafari AM, Wenger NK. Secondary Prevention of Coronary Heart Disease. Arch Phys Med Rehabil 1998;79:1006-1017. e. Book chapters: 1. Garas S, Zafari AM. Myocardial Infarction. http://www.emedicine.com/med/topic1567.htm. 2000 2. Zafari AM, Harrison DG, Griendling KK. Vascular Oxidant Stress and Nitric Oxide 8
  • 9. A. Maziar Zafari Curriculum Vitae Bioactivity. In Panza JA, Cannon RO III (eds): Endothelium, Nitric Oxide, and Atherosclerosis. Futura Publishing Co, Inc, Armonk, NY, 1999. f. Books edited and written: 1. Zafari AM. The Image of Mohammad by Ali Shariati. Translation into German; Göttingen 1979. 2. Zafari AM. The Swallow’s Flight. Selected poetry in Persian. The Art Association of Cologne, Cologne 1984. 3. Zafari AM. Psychosomatic Aspects in the Medieval Medicine of Persia. University of Cologne Publishing, Cologne 1990, (ISBN 3-925341-52-8). 4. Shirani J, Zafari AM. The Golden Goblet by Georg Trakl. Translation into Persian. Iran Books Publishing, Bethesda 1994, (ISBN 0-936347-37-6). 5. Zafari AM. Träume, Alpträume. Selected poetry in German. Internationales Kulturwerk Publishing, Hildesheim 1996, (ISBN 3-910069-65-7). 6. Klotz T, Zafari AM. Internal Medicine in Questions and Answers. First 3 editions, Jungjohann Publishing, Stuttgart 1991, 1993, 1995 (ISBN 3-437-41500-X). 7. Klotz T, Zafari AM. Internal Medicine in Questions and Answers. Revised 4th edition, Gustav Fischer Publishing, Stuttgart 1997 (ISBN 3-437-41500-X). 8. Klotz T, Zafari AM, Schupp M. Internal Medicine in Questions and Answers. Revised and expanded 5th edition, Urban & Fischer Publishing, München 2002 (ISBN 3-437-41501-8). i. Other publications: 1. Harb ZF, Khoshnood K, Zafari AM, Sadigh M. HIV Experience in a Community Hospital in Connecticut. Conn Med 1992;56:611. 2. Pasha T, Zafari AM, Sadigh M, Simms M, Miller D. St. Mary’s Autopsy Project: A Retrospective Review of Autopsies in the Last Two Years in a Community Hospital. Conn Med 1992;56:618. 3. Zafari AM, Shirani J, Roberts WC. Frequency and Extent of Coronary Calcific Deposits in Men between Ages of 81 to 90 Years. Conn Med;57:596. 4. Shirani J, Zafari AM, Nixon JV, Roberts WC. Morphologic Features of Fossa Ovalis Membranes. J Am Soc Echo 1994;S48, Abstract 8D. 5. Zafari AM. Abu-Ali Sina. Avicenna Update in Internal Medicine. Avicenna Homepage 1996, http://www.yale.edu/avicenna. 6. Zafari AM, Alexander RW, Minieri C, Akers M, Lassègue B, Griendling KK. Arachidonic Acid Metabolites Mediate Angiotensin II-induced Hypertrophy by Stimulation of NADH/NADPH Oxidase Activity in Cultured Vascular Smooth Muscle Cells. ASBMB/ASIP/AAI Joint Meeting 1996, A1013, Abstract 80. 7. U-Fukai M, Fukui T, Zafari AM, Griendling KK. The Cytochrome b558 α-Subunit is Required for Activation of the NADPH Oxidase and Angiotensin II-induced Hypertrophy in Cultured Vascular Smooth Muscle Cells. FASEB 1996, A271, Abstract 9
  • 10. A. Maziar Zafari Curriculum Vitae 1560. 8. Zafari AM, Ushio-Fukai M, Howard AB, Harrison DG, Taylor RW, Griendling KK. Angiotensin II Increases Intracellular NADH/NADPH Oxidase-dependent Hydrogen Peroxide in Cultured Vascular Smooth Muscle Cells. Circulation 1996;94:I-280, Abstract 1630. 9. Howard AB, Zafari AM, Griendling KK, Taylor RW. Cyclic Strain Increases Phospholipase A2 Activity in Endothelial Cells. Circulation 1996;94:I-444, Abstract 2595. 10. Zafari AM, Davidoff MN, Valppu L, Cotsonis GA, Lassègue B, Griendling KK. The A640G p22phox Polymorphism in Coronary Artery Disease. Circulation 2000;102:II-303, Abstract 1483. 11. Wyche KE, Griendling KK, Dikalov SI, Austin H, Sorescu D, Harrison DG, Zafari AM. The C242T p22phox Polymorphism of the NADPH Oxidase is Associated With Reduced Superoxide Production in Human Neutrophils. AHA Scientific Conference on Molecular, Integrative, and Clinical Approaches to Myocardial Ischemia, August 2001; Abstracts, P7. 12. Publication Committee for the VMAC Investigators. Intravenous Nesiritide vs. Nitroglycerin for Treatment of Decompensated Congestive Heart Failure - A Randomized Controlled Trial. JAMA 2002;287:1531-1540. 13. Zafari AM, Harrison DG. Free Radicals in Heart Failure: Therapeutic Targets for Old and New Drugs. Congest Heart Fail 2002;8:129-130. 14. Rao S, Sheikh A, Austin H, Choudhary G, Zafari AM. The eNOS4 Polymorphism Does Not Predict Severity of CAD. FRBM 2002;33: (II)S366. 10